"if the CEO and his team are as sharp as stated (by several folks here) then this should have already been done."
A share price of $1.40 a pop for a product that hasn't been endorsed by the ESSENTIAL watchdog government agency is a pretty damn good indicator of a razor-sharp CEO and his team IMHO.
Revenue, revenue, revenue. That's what the DuPont deal was all about way back when, but because it didn't come to pass, dilution may well be in the cards for us. I'm not too fearful of dilution here for a number of reasons:
1. DR has shown that he is very frugal with the printing press over the years. There's no reason to think that practice won't continue.
2. I agree with Training Surgeons that the diffeence-maker for this technology and this company is proving up the claim of suturing organs with no necrosis. If LTC can power ahead with this technology, the amounts discussed by us on this board won't mean much.
3. Big names do cost $$. But our big names are willing to defer their payday until the technology that they independently assessed begins to reap rewards. They know much, much more than we do. If they like it, I love it.
The best PR for this company if FDA approval.
News 
Market Data 
Discover 
